PolarityTE (PTEIQ) Competitors $0.13 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends PTEIQ vs. ARTL, TTNP, NBY, GRTS, SNPX, ONCT, LIXT, PPBT, NCNA, and INMShould you be buying PolarityTE stock or one of its competitors? The main competitors of PolarityTE include Artelo Biosciences (ARTL), Titan Pharmaceuticals (TTNP), NovaBay Pharmaceuticals (NBY), Gritstone bio (GRTS), Synaptogenix (SNPX), Oncternal Therapeutics (ONCT), Lixte Biotechnology (LIXT), Purple Biotech (PPBT), NuCana (NCNA), and InMed Pharmaceuticals (INM). These companies are all part of the "pharmaceutical products" industry. PolarityTE vs. Artelo Biosciences Titan Pharmaceuticals NovaBay Pharmaceuticals Gritstone bio Synaptogenix Oncternal Therapeutics Lixte Biotechnology Purple Biotech NuCana InMed Pharmaceuticals Artelo Biosciences (NASDAQ:ARTL) and PolarityTE (NASDAQ:PTEIQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, community ranking, risk, analyst recommendations, institutional ownership, valuation and earnings. Does the MarketBeat Community favor ARTL or PTEIQ? Artelo Biosciences received 42 more outperform votes than PolarityTE when rated by MarketBeat users. CompanyUnderperformOutperformArtelo BiosciencesOutperform Votes4275.00% Underperform Votes1425.00% PolarityTEN/AN/A Which has preferable earnings & valuation, ARTL or PTEIQ? PolarityTE has higher revenue and earnings than Artelo Biosciences. Artelo Biosciences is trading at a lower price-to-earnings ratio than PolarityTE, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtelo BiosciencesN/AN/A-$9.29M-$2.87-0.39PolarityTE$810K1.14-$7.83M-$3.28-0.04 Do analysts rate ARTL or PTEIQ? Artelo Biosciences presently has a consensus target price of $5.00, indicating a potential upside of 342.44%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Artelo Biosciences is more favorable than PolarityTE.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50PolarityTE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to ARTL or PTEIQ? In the previous week, Artelo Biosciences had 7 more articles in the media than PolarityTE. MarketBeat recorded 7 mentions for Artelo Biosciences and 0 mentions for PolarityTE. PolarityTE's average media sentiment score of 0.00 beat Artelo Biosciences' score of -0.25 indicating that PolarityTE is being referred to more favorably in the news media. Company Overall Sentiment Artelo Biosciences Neutral PolarityTE Neutral Do institutionals and insiders believe in ARTL or PTEIQ? 0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 11.8% of PolarityTE shares are held by institutional investors. 0.8% of Artelo Biosciences shares are held by insiders. Comparatively, 5.4% of PolarityTE shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, ARTL or PTEIQ? Artelo Biosciences has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, PolarityTE has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Is ARTL or PTEIQ more profitable? Artelo Biosciences' return on equity of -104.59% beat PolarityTE's return on equity.Company Net Margins Return on Equity Return on Assets Artelo BiosciencesN/A -104.59% -94.06% PolarityTE N/A -106.08%-76.91% SummaryArtelo Biosciences beats PolarityTE on 9 of the 16 factors compared between the two stocks. Ad Genesis Gold GroupBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Get PolarityTE News Delivered to You Automatically Sign up to receive the latest news and ratings for PTEIQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTEIQ vs. The Competition Export to ExcelMetricPolarityTEBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$923,000.00$140.67M$5.11B$8.84BDividend YieldN/A3.50%5.05%4.07%P/E Ratio-0.04326.96108.8915.88Price / Sales1.1415,580.351,233.2287.15Price / CashN/A12.1239.9336.27Price / Book0.057.336.946.36Net Income-$7.83M-$18.76M$119.18M$226.00M7 Day Performance13.60%0.05%-1.36%-0.02%1 Month Performance20.55%8.22%-3.27%1.95%1 Year PerformanceN/A25.38%32.40%27.80% PolarityTE Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTEIQPolarityTEN/A$0.13flatN/A+50.1%$923,000.00$810,000.00-0.0460Gap DownARTLArtelo Biosciences3.0203 of 5 stars$1.13-1.7%$5.00+342.4%-8.7%$3.65MN/A0.005Analyst RevisionTTNPTitan Pharmaceuticals0.7991 of 5 stars$3.93+7.7%N/A-49.2%$3.58M$180,000.000.0010News CoverageNBYNovaBay Pharmaceuticals0.5204 of 5 stars$0.72+1.4%$0.85+18.1%-93.7%$3.53M$14.73M-0.0130GRTSGritstone bio1.1614 of 5 starsN/A$2.17+∞N/A$3.50M$496,000.00-0.03190News CoverageGap DownHigh Trading VolumeSNPXSynaptogenix2.0975 of 5 stars$2.57-3.0%$14.00+444.7%-59.2%$3.50MN/A0.004ONCTOncternal Therapeutics2.266 of 5 stars$1.16+1.8%$20.00+1,624.1%-83.1%$3.43M$790,000.000.0030Analyst ForecastLIXTLixte Biotechnology0.0581 of 5 stars$1.52+2.0%N/A-49.7%$3.42MN/A0.003PPBTPurple Biotech1.8213 of 5 stars$2.54+2.8%$33.00+1,199.2%N/A$3.38MN/A-0.2920NCNANuCana3.0285 of 5 stars$1.27-0.8%$25.00+1,868.5%-88.1%$3.35MN/A-0.1130INMInMed Pharmaceuticals0.2114 of 5 stars$4.65+9.9%N/A-47.8%$3.35M$4.60M-0.3313 Related Companies and Tools Related Companies Artelo Biosciences Competitors Titan Pharmaceuticals Competitors NovaBay Pharmaceuticals Competitors Gritstone bio Competitors Synaptogenix Competitors Oncternal Therapeutics Competitors Lixte Biotechnology Competitors Purple Biotech Competitors NuCana Competitors InMed Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PTEIQ) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolarityTE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolarityTE With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
